– CHINA, Hong Kong – Hutchison China MediTech Limited (AIM/Nasdaq: HCM) today announces that with effect from March 1, 2017:
- Mr Graeme Allan Jack has been appointed as Independent Non-executive Director, Chairman of Audit Committee and member of Remuneration Committee;
- Mr Michael Howell tendered his resignation as Independent Non-executive Director, Chairman of Audit Committee and member of Remuneration Committee.
Mr Simon To, Chairman of Chi-Med said “With the appointment of Mr Jack, the Company now completes the process of refreshing the Board by replacing its three former Independent Non-executive Directors who had each served the Company in excess of nine years, in line with our objective of best-practice corporate governance.”
Mr To added “We welcome to the Board Mr Jack whose experience in finance and accounting will be important for the Company and we thank Mr Michael Howell for his invaluable contributions to the Company during his tenure.”
As an independent non-executive director, Mr Jack is not involved in the day-to-day management or operation of any of the aforementioned companies.
Further, Mr Jack is currently an independent trustee of two provident funds established for the benefit of the employees of CK Hutchison Holdings Limited, the majority shareholder of the Company and, in that capacity, received customary compensation out of the relevant trust funds for such services. He is expected to relinquish his trustee position in about two months’ time on completion of the replacement formalities. Within the past five years, he was previously a director of Graff Diamonds Corporation from May to July 2012.
He holds a Bachelor of Commerce degree and is a Fellow of the Hong Kong Institute of Certified Public Accountants and an Associate of Chartered Accountants Australia and New Zealand.
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
For more information : http://www.chi-med.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
